Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT04406727
PHASE3
UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
Sponsor: United BioPharma
View on ClinicalTrials.gov
Summary
The purpose of this phase III study is to evaluate the efficacy between treatments (UB-421 Arm vs. Placebo Arm) by measuring the proportion of subjects with reduction in HIV-1 RNA viral load.
Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial With UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-12-01
Completion Date
2026-06-30
Last Updated
2023-04-24
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
UB-421
UB-421 in combination with their ARV
OTHER
Antiretroviral (ARV)
Antiretroviral (ARV)